龔麗友
[摘要] 目的 觀察使用格列齊特緩釋片、二甲雙胍、阿卡波糖聯合治療對2型糖尿病的降糖作用和對胰島素的影響。方法 選擇該院于2018年4月—2019年4月期間收治的120例2型糖尿病患者為該次研究對象,將所有患者按照治療方案的不同分為對照組(n=60)與研究組(n=60),對照組采用二甲雙胍治療方案,研究組應用格列齊特緩釋片、二甲雙胍、阿卡波糖聯合治療方案,對比分析兩組患者血糖水平、空腹胰島素和胰島素抵抗指數。 結果 觀察組患者空腹血糖、餐后2 h血糖明顯低于對照組,研究組空腹胰島素高于對照組,同時胰島素抵抗指數低于對照組(P<0.05)。 結論 針對2型糖尿病患者采用格列齊特緩釋片、二甲雙胍、阿卡波糖聯合治療效果尤為顯著,能夠有效降低患者血糖水平,提高體內胰島素水平,同時降低胰島素抵抗作用,臨床使用價值較高。
[關鍵詞] 2型糖尿病患者;格列齊特緩釋片;二甲雙胍;阿卡波糖;聯合治療
[中圖分類號] R587.1? ? ? ? ? [文獻標識碼] A? ? ? ? ? [文章編號] 1672-4062(2020)02(b)-0048-02
[Abstract] Objective To observe the hypoglycemic effect and insulin effect of type 2 diabetes mellitus treated with glipizide sustained-release tablets, metformin, and acarbose. Methods A total of 120 patients with type 2 diabetes who were treated in our hospital from April 2018 to April 2019 were selected as the research subjects. All patients were divided into control group(n=60 cases) and study group(n=60 cases) according to different treatment plans, the control group was treated with metformin, and the study group was treated with glipizide sustained-release tablets, metformin, and acarbose. The blood glucose levels, fasting insulin, and insulin resistance index of the two groups were compared and analyzed. Results The fasting blood glucose and 2h postprandial blood glucose of the observation group were significantly lower than those of the control group. The fasting insulin of the study group was higher than that of the control group, and the insulin resistance index was lower than that of the control group(P<0.05). Conclusion The combination of Glezide extended-release tablets, metformin, and acarbose is particularly effective for patients with type 2 diabetes, which can effectively reduce blood glucose levels, increase insulin levels in the body, and reduce insulin resistance.
[Key words] Patients with type 2 diabetes; Glipizide sustained-release tablets; Metformin; Acarbose; Combination therapy
隨著社會經濟的發展,人均營養攝入量顯著增加,2型糖尿病發病率逐年升高,2型糖尿病病情不易控制,后期易發生多種并發癥,嚴重影響患者的生活質量[1]。有效地降糖治療對2型糖尿病非常重要,臨床上常用的降糖藥物有二甲雙胍、阿卡波糖、格列美脲、格列齊特等[2]。該文中,將對2型糖尿病患者實施格列齊特緩釋片、二甲雙胍、阿卡波糖聯合治療的臨床效果展開討論分析,現分析2018年4月—2019年4月間該院收治的120例2型糖尿病患者的臨床資料,報道如下。
1? 資料與方法
1.1? 一般資料
選擇該院收治的120例2型糖尿病患者為該次研究對象,所有患者均被確診為2型糖尿病,將其按照治療方案的不同,分為對照組60例,男32例,女28例,年齡(75.85±8.85)歲和研究組60例,男31例,女29例,年齡(75.45±8.36)歲。……